“J.E. Flynn Capital, LLC, General Partner”

a.k.a.:  “J.E. Flynn Capital LLC, General Partner”

As a Name:  Registrant, Group Member and/or Signatory

        

Latest Filing:  4/24/24  as  ↓Signatory

        

As:  Signatory  (Director, Officer, Attorney, Accountant, Banker, Agent, etc.)

“J.E. Flynn Capital, LLC, General Partner” has been a Signatory for/with  34  Filers:

        

As Of	Filer			Filings       #        Latest		Issuer     (Primary)
4/24/24		NY	Flynn James E	551	SC 13G	MA	Cullinan Therapeutics, Inc.
3/12/24		NY	Deerfield Management Co., L.P. (Series C)	351	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Mgmt IV, L.P.	28	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Mgmt L.P.	341	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Partners, L.P.	173	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Private Design Fund IV, L.P.	28	4	PA	AdaptHealth Corp.
2/16/24		NY	Deerfield Healthcare Innovations Fund, L.P.	20	4	PA	Larimar Therapeutics, Inc.
2/16/24		NY	Deerfield Mgmt HIF, L.P.	20	4	PA	Larimar Therapeutics, Inc.
2/16/24		NY	Deerfield Mgmt III, L.P.	65	4	PA	Larimar Therapeutics, Inc.
2/16/24		NY	Deerfield Private Design Fund III, L.P.	65	4	PA	Larimar Therapeutics, Inc.
8/24/23		CA	RayzeBio, Inc.	2	S-1	—
5/10/22		NY	Deerfield Mgmt V, L.P.	4	4	MA	PepGen Inc.
5/10/22		NY	Deerfield Private Design Fund V, L.P.	2	4	MA	PepGen Inc.
10/1/21		MA	Xilio Therapeutics, Inc.	2	S-1	—
9/16/21		CA	Vincerx Pharma, Inc.	2	424B3	—
8/23/21		CA	Acutus Medical, Inc.	1	8-K	—
7/13/21		NY	Deerfield Special Situations Fund, L.P.	255	4	CA	Mirum Pharmaceuticals, Inc.
6/4/21		CA	LENZ Therapeutics, Inc.	2	S-1	—
3/22/21		CO	Aytu Biopharma, Inc.	2	8-K	—
3/22/21		TX	Neos Therapeutics, Inc.	3	8-K	—
			More...  Please Sign In to list all 34 of them.

“J.E. Flynn Capital, LLC, General Partner” has/had a Signatory interest in  152  Issuers:

As Of	Issuer			Filings       #        Latest		With Filer     (Primary)
4/24/24		MA	Cullinan Therapeutics, Inc.	1	SC 13G	NY	Flynn James E
4/4/24		CA	Ventyx Biosciences, Inc.	1	SC 13G	NY	Flynn James E
3/12/24		PA	AdaptHealth Corp.	6	4	NY	Deerfield Management Co., L.P. (Series C)
2/16/24		PA	Larimar Therapeutics, Inc.	5	4	NY	Deerfield Management Co., L.P. (Series C)
2/12/24		MA	Nuvalent, Inc.	4	SC 13G/A	NY	Flynn James E
2/12/24		TX	Nuo Therapeutics, Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24		CA	Kura Oncology, Inc.	4	SC 13G/A	NY	Flynn James E
2/12/24			Merus N.V.	3	SC 13G/A	NY	Flynn James E
2/12/24		MA	Deciphera Pharmaceuticals, Inc.	5	SC 13G/A	NY	Flynn James E
2/12/24		FL	Catalyst Pharmaceuticals, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		MA	Vigil Neuroscience, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		CA	Singular Genomics Systems, Inc.	6	SC 13G/A	NY	Flynn James E
2/12/24		CA	Pulmonx Corp.	5	SC 13G/A	NY	Flynn James E
2/12/24		DE	Prelude Therapeutics Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24		VA	Owens & Minor Inc./VA	2	SC 13G/A	NY	Flynn James E
2/12/24		NY	Oscar Health, Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24			Mallinckrodt plc	4	SC 13G/A	NY	Flynn James E
2/12/24		MA	HilleVax, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		TX	Enhabit, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		NY	DocGo Inc.	2	SC 13G/A	NY	Flynn James E
			More...  Please Sign In to list all 152 of them.